2013 Apr 15 Annual Report 2012 - Phosphagenics

More documents

Recommendations

Info

Animal Health Products HORSE FEED AND SUPPLEMENTS In 2012 together with our partner, Equine Nutrition Australia, we successfully launched products targeted at the thoroughbred industry. In June we began selling three new horse feed products aimed at yearlings and in October we gained approval and launched two new products in Singapore after gaining approval for their sale from the Singapore Turf Club. 14 In the recent Magic Millions sales a horse which had been raised on TPM ® /horsefeed products was sold to leading Australian horse trainer, Gai Waterhouse. In 2013 we are hopeful that arrangements put in place in 2012 will open up further markets (predominantly Asia) for our products. MASTITIS In March 2011, Phosphagenics completed a deal with Mastitis Management Australia to investigate the use of a TPM ® based natural formula to target the disease of mastitis in cows. Mastitis affects 15% of the global herd with the losses from lost production and medication averaging a loss per cow of $200 (over $2billion in the US). Based on the size of the herd in developed countries it is clearly a multi-billion dollar problem for farmers and represents a huge market opportunity. The current solution of using antibiotics does cause some concern. 2013 promises to be a year when trial work in this area should increase significantly and take us closer towards commercialisation. PHOSPHAGENICS ANNUAL REPORT 2012
Personal Care ASHLAND INC (FORMERLY ISP) Ashland Inc sells Vital ET ® for formulation into personal care products. Its customers include the major known personal care brands. Vital ET ® has been promoted actively as a superior way to deliver Vitamin E. The supply of Vital ET ® which is manufactured in Australia by Phosphagenics has been steadily growing and contributing to revenue. The Ashland contract was the first commercial deal finalised by your company having been signed in 2003. LE MÉTIER DE BEAUTÉ The agreement with Le Metier has been in place since 2009 and been contributing to revenue since. Le Metier is a niche market player selling expensive cosmetics in up market retailers such as Neiman Marcus and Bergdorf Goodman. INTAS Intas Pharmaceuticals is an Indian company which reached an agreement with Phosphagenics to market three anti-ageing formulations supplied by us. The launch of these three products into the Indian market is scheduled for 2013. GNC GNC is one of the largest companies in the world specialising in the area of health and wellbeing. GNC has agreed to sell a firming cream which has been formulated and manufactured by Phosphagenics. GNC will use its extensive retail network (7,900 globally and more than 6,000 in the US), as well as, a significant on line capability to sell the product. This product is expected to launch in the first half 2013. LIVE WELL. 15 PERSONAL CARE
Page 1 and 2: 20 12 Annual Report PHOSPHAGENICS P
Page 3 and 4: highlights March... April... May...
Page 5 and 6: 03 Jonathan Addison Chairman & Inde
Page 7 and 8: COLLABORATIONS Strategic Collaborat
Page 9 and 10: The Phosphagenics Evolution THE STO
Page 11 and 12: “ We also reached agreement with
Page 13 and 14: Overview of our opioid development
Page 15: 13 is branded as Butrans or Norspan
Page 19 and 20: BEAUTY IS MORE THAN SKIN DEEP 17 EL
Page 21 and 22: cellulite contour crème BioElixia
Page 23 and 24: Intellectual Property Title Countri
Page 25 and 26: 2009 2008 2007 2006 6.8 7.8 22.2 23
Page 27 and 28: DR ESRA OGRU (AGED 37 YEARS) BSC (H
Page 29 and 30: Senior Management DR PAUL GAVIN Chi
Page 31 and 32: Phosphagenics Limited ABN 32 056 48
Page 33 and 34: Directors’ Report Your directors
Page 35 and 36: Directors’ Report continued Looki
Page 37 and 38: Directors’ Report continued Commi
Page 39 and 40: Directors’ Report continued REMUN
Page 43 and 44: Directors’ Report continued Share
Page 45 and 46: Directors’ Report continued Share
Page 47 and 48: Exercise Price Expiry Date Net othe
Page 49 and 50: Exercise Price Expiry Date Net othe
Page 51 and 52: Fair value per performance right at
Page 55 and 56: Auditors Independence Declaration 5
Page 57 and 58: Corporate Governance Statement cont
Page 67 and 68:
Consolidated statement of fi nancia
Page 69 and 70:
Consolidated statement of changes i
Page 71 and 72:
Notes to the consolidated fi nancia
Page 73 and 74:
Application date of standard Impact
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Independent Auditor’s Report 111
Page 115 and 116:
Additional Shareholder Information
Page 117 and 118:
Additional Shareholder Information
Page 119:
corporate directory Phosphagenics L
show all

2013 Apr 15 Annual Report 2012 - Phosphagenics

Create successful ePaper yourself

Delete template?

Save as template?